Under today's deal, all of UC Health's medical centers will work with GeneDx and have access to more than 400 of the firm's tests for rare hereditary disorders.
The company awaits a decision from Medicare contractor Novitas, which issued a positive LCD in 2016 but withdrew it in response to a negative LCD from Palmetto.
The company, which is part of Opko Health's BioReference Laboratories, recently hired a new managing director, who plans to expand the firm's market and testing portfolio.
Experts at CAP16 said most practicing pathologists operate within specialties and rarely cross the divide into other test disciplines, which thwarts optimal patient care.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
